Drug ads must now show you the price—a first step toward transparency

What it does

This bill requires pharmaceutical manufacturers to disclose the wholesale acquisition cost (list price) of prescription drugs in direct-to-consumer advertisements, effective July 1, 2026. The disclosure must appear in all ads for drugs covered by Medicare or Medicaid, except those costing less than $35 for a 30-day supply. Manufacturers who fail to comply face civil penalties up to $100,000 per violation.

Why we flagged it

The bill's core mechanism is a straightforward disclosure requirement—manufacturers must show list prices in ads. It is not a price-control measure, a subsidy, or a deregulation; it is a transparency obligation that shifts information asymmetry in favor of consumers.

What the text implies

• The $35 exemption threshold may create a perverse incentive for manufacturers to keep list prices just below $35 to avoid disclosure, even if actual out-of-pocket costs are higher due to insurance structures.
• Disclosure of wholesale acquisition cost (WAC) does not reflect actual patient out-of-pocket costs, which vary by insurance plan, deductible status, and copay structure. Patients may still be confused about what they will actually pay.

The full analysis lists 4 implications of this text.

Who it affects

Ordinary citizens gain access to drug pricing information at the point of advertising, enabling more informed purchasing decisions and potentially reducing wasteful spending on expensive alternatives when cheaper options exist. The bill does not restrict access to medications, impose new costs on patients, or shield any party from liability—it simply mandates transparency that currently exists only behind paywalls or in specialized databases.